Page 2 of 4 Previous | Next 
  • SCOTT'S WEB LOG  |  WEDNESDAY, JANUARY 9, 2008
    [Clinical Trial, Type 1 Diabetes] Protein Treatments to Cure Type 1 Diabetes?
    Proteins are being investigated for use in treating a variety of diseases because they can influence cell behavior by fueling or dampening certain molecular signals, therefore their use may be used to influence the regeneration of certain cells, in the case of diabetes, the pancreatic beta cells. This falls under the broader diabetes research objective to investigate inducing beta cell regeneration. The UF research team's novel approach is described online in the journal Diabetes.
  • SCOTT'S WEB LOG  |  WEDNESDAY, JANUARY 9, 2008
    [Clinical Trial, Type 1 Diabetes] Protein Treatments to Cure Type 1 Diabetes?
    Proteins are being investigated for use in treating a variety of diseases because they can influence cell behavior by fueling or dampening certain molecular signals, therefore their use may be used to influence the regeneration of certain cells, in the case of diabetes, the pancreatic beta cells. This falls under the broader diabetes research objective to investigate inducing beta cell regeneration. The UF research team's novel approach is described online in the journal Diabetes.
  • TOPIX  |  WEDNESDAY, NOVEMBER 26, 2014
    [Clinical Trial, Type 1 Diabetes] The Artificial Pancreas Shown to Improve the Treatment of Type 1 Diabetes
    The world''s first clinical trial comparing three alternative treatments for type 1 diabetes was conducted in MontrA©al by researchers at the IRCM and the University of Montreal, led by endocrinologist Dr. RA©mi Rabasa-Lhoret. The study confirms that the external artificial pancreas improves glucose control and reduces the risk of hypoglycemia compared to conventional diabetes treatment
  • TOPIX  |  TUESDAY, APRIL 5, 2016
    [Clinical Trial, Type 1 Diabetes] Type 1 Diabetes Cure? -- Doctor's In-depth Interview
    Professor of Medicine and Director of the Comprehensive Diabetes Center at UAB talks about a new treatment for type 1 diabetes. Dr. Shalev: This is a clinical trial to test verapamil, which is a commonly used blood pressure medication, for whether it may have some beneficial effect in the context of new onset Type I diabetes Anath Shalev, M.D.,
  • TOPIX  |  THURSDAY, JULY 7, 2016
    [Clinical Trial, Type 1 Diabetes] Healthier Me: Trial Looks to Cure Type 1 Diabetes
    Valley News Team's, Danielle Barber, explains Sanford's first-of-its-kind clinical trial that doctors hope will cure the chronic condition. "He He was very moody," said Diane Capouch, Hunter's mother
  • ANNETICS  |  WEDNESDAY, MARCH 24, 2010
    [Clinical Trial, Type 1 Diabetes] A Role for Leptin in Type 1 Diabetes?
    Wednesday, March 24, 2010 A Role for Leptin in Type 1 Diabetes? While glancing over todays science headlines, I noticed a write-up in Science Daily of a study from UT Southwestern Medical Center involving the administration of recombinant leptin (Amlylin Pharmaceuticals) to non-obese mice (which serve as a model for human type 1 diabetes). So it is unknown whether leptin would have as strong of an effect in humans with type 1.
  • DIABETES IN CONTROL  |  THURSDAY, FEBRUARY 13, 2014
    [Clinical Trial, Type 1 Diabetes] 180 Diabetes Drugs in Development
    America''s biopharmaceutical research companies currently are developing 180 new medicines to help the nearly 400 million people who have diabetes worldwide. These medicines in development -- all either in clinical trials or under review by the FDA -- include 30 for type 1 diabetes, 100 for type 2 and 52 for diabetes-related conditions.
  • DIABETES MINE  |  TUESDAY, MARCH 19, 2013
    [Clinical Trial, Type 1 Diabetes] Animas’ Hypo-Hyper Minimizer Aims for Diabetes “Cruise Control”
    Both vibrate… The post Animas’ Hypo-Hyper Minimizer Aims for Diabetes “Cruise Control” appeared first on DiabetesMine: the all things diabetes blog. Snuggled up in my bed under the warm covers, all I want to do is keep my eyes closed. But, no. My darn insulin pump and continuous glucose monitor (CGM) just won’t shut up and let me sleep.
  • INSULIN NATION  |  TUESDAY, NOVEMBER 18, 2014
    [Clinical Trial, Type 1 Diabetes] Thankful for the Pinpricks
    It’s easy to find something to complain about while living with Type 1 diabetes. While these daily reminders of Type 1 are all negatives, they can also be something for which to be extremely grateful. It follows the story of a young girl who was diagnosed with Type 1 diabetes in 1919. At this time, the only accepted form of treatment for diabetes was starvation. Thus, starvation was often the only prescribed treatment for diabetes.
  • INSULIN NATION  |  TUESDAY, JUNE 23, 2015
    [Clinical Trial, Type 1 Diabetes] Bigfoot’s Plan To Get An Artificial Pancreas to Market
    Bigfoot Biomedical is trying to quickly bring an artificial pancreas to market, one based on the homemade design of Bryan Mazlish, whose wife and son have Type 1. Mazlish, now the company’s chief technology officer, was hailed in diabetes device tinkering circles for hacking into a pump and meter to create a smart pump system that automatically adjusts insulin levels based on blood sugar readings.
  • TOPIX  |  WEDNESDAY, SEPTEMBER 13, 2017
    [Clinical Trial, Type 1 Diabetes] Study: New oral drug helps control glucose, reduces need for insulin in patients with type 1 diabetes
    A University of Colorado Anschutz Medical Campus study finds sotagliflozin helps control glucose and reduces the need for insulin in patients with type 1 diabetes. Principal results were published today in the New England Journal of Medicine of a global Phase 3 clinical trial in patients with type 1 diabetes treated with sotagliflozin
  • SCOTT'S WEB LOG  |  THURSDAY, NOVEMBER 2, 2006
    [Clinical Trial, Type 1 Diabetes] Stem cell insulin offers hope to type 1 diabetics
    Interesting news, since one of the main arguments that embryonic stem cell research opponents like to use is that embryonic stem cells have never been coaxed into any type of human tissue, that umbilical cord cells have the same potentential (which they do not). Regardless, this is the first time that American researchers were able to coax embryonic stem cells into insulin-producing beta cells, with the idea that these could be used as replacements someday in patients with type 1 diabetes.
  • SCOTT'S WEB LOG  |  THURSDAY, NOVEMBER 2, 2006
    [Clinical Trial, Type 1 Diabetes] Stem cell insulin offers hope to type 1 diabetics
    Interesting news, since one of the main arguments that embryonic stem cell research opponents like to use is that embryonic stem cells have never been coaxed into any type of human tissue, that umbilical cord cells have the same potentential (which they do not). Regardless, this is the first time that American researchers were able to coax embryonic stem cells into insulin-producing beta cells, with the idea that these could be used as replacements someday in patients with type 1 diabetes.
  • JOSLIN DIABETES CENTER  |  WEDNESDAY, NOVEMBER 5, 2014
    [Clinical Trial, Type 1 Diabetes] Pursuing a Kidney Clue: Fighting Type 1 Kidney Failure
    Throughout National Diabetes Month, we will be sharing insights into Joslin’s innovations in care for diabetes and its complications as part of our mission of preventing, treating and curing diabetes. Our vision is a world free of diabetes and its complications. Our data revealed type 1 diabetes patients with moderately high serum uric acid levels are at high risk of losing kidney function,” says Joslin researcher Alessandro Doria , M.D.,
  • JOSLIN DIABETES CENTER  |  MONDAY, MARCH 9, 2015
    [Clinical Trial, Type 1 Diabetes] Pursuing a Kidney Clue: Fighting Type 1 Kidney Failure
    5, 2014 as part of National Diabetes Month. Our data revealed type 1 diabetes patients with moderately high serum uric acid levels are at high risk of losing kidney function,” says Joslin researcher Alessandro Doria , M.D., Director of Clinical Research, and renal specialist Robert C. million to lead a five-year clinical trial titled Preventing Early Renal Function Loss in Diabetes , or PERL. This article originally appeared on Nov.
  • JOSLIN DIABETES CENTER  |  WEDNESDAY, DECEMBER 31, 2014
    [Clinical Trial, Type 1 Diabetes] 14 from ’14: The Best of This Year from Speaking of Diabetes, Part 2
    Throughout 2014 we’ve brought you stories about everything from a calorie-burning fat, to how to deal with diabetes stress, to inspirational athletes with diabetes. Emotions & Blood-Sugar Levels: How Diabetes Can Affect Your Mood. Investigator in the Section on Clinical, Behavioral & Outcomes Research. Diabetes can affect both your physical and mental health. The same goes for the stress of managing diabetes 24/7.
  • SCIENCE DAILY  |  WEDNESDAY, NOVEMBER 26, 2014
    [Clinical Trial, Type 1 Diabetes] Artificial pancreas shown to improve treatment of type 1 diabetes
    The world’s first clinical trial comparing three alternative treatments for type 1 diabetes demonstrates that the external artificial pancreas improves glucose control and reduces the risk of hypoglycemia compared to conventional diabetes treatment
  • INSULIN NATION  |  MONDAY, NOVEMBER 25, 2013
    [Clinical Trial, Type 1 Diabetes] Skin Drug Reduces Need for Insulin
    Researchers have discovered that a skin drug used for psoriasis seems to maintain insulin production in the bodies of people recently diagnosed with Type 1 diabetes. In a Phase II clinical trial, researchers with the National Institute of Health gave either the drug alefacept or a placebo to 49 people with Type 1 diabetes for two 12-week periods, with a 12-week “rest” period in between.
  • TOPIX  |  SUNDAY, FEBRUARY 6, 2011
    [Clinical Trial, Type 1 Diabetes] Key elements for successful intensive insulin pump therapy in individuals with type 1 diabetes
    Diabetes Research and Clinical Practice Key: citeulike:8773143 Posts Export Citation Likes Abstract Clinical trials have demonstrated that in individuals with type 1 diabetes the use of CSII pump resulted in better glucose control
  • YOUR DIABETES MAY VARY  |  WEDNESDAY, MAY 7, 2008
    [Clinical Trial, Type 1 Diabetes] From the News Wire: Novel Combination Treatment for Type 1 Diabetes
    I haven't had time yet to read this with care - first read is very interesting: DiaKine Therapeutics and Kinexum Metabolics to Develop Novel Combination Treatment to Type 1 Diabetes Lisofylline and INGAP Peptide Combo Therapy Set for Phase 2 Clinical Trial CHARLOTTESVILLE, Va. A Phase 2 human clinical trial with the new combination therapy, consisting of DiaKine’s Lisofylline (LSF) and Kinexum’s INGAP peptide, is expected to begin in late 2008.
  • JOSLIN DIABETES CENTER  |  MONDAY, MARCH 7, 2016
    [Clinical Trial, Type 1 Diabetes] Pursuing a Kidney Clue: Fighting Type 1 Kidney Failure
    Throughout the month of March, the Joslin Blog is highlighting stories about your kidneys and diabetes. Our data revealed type 1 diabetes patients with moderately high serum uric acid levels are at high risk of losing kidney function,” says Joslin researcher Alessandro Doria , M.D., Director of Clinical Research, and renal specialist Robert C. million to lead a five-year clinical trial titled Preventing Early Renal Function Loss in Diabetes , or PERL.
  • TOPIX  |  SATURDAY, AUGUST 15, 2015
    [Clinical Trial, Type 1 Diabetes] Key elements for successful intensive insulin pump therapy in individuals with type 1 diabetes.
    Clinical trials have demonstrated that in individuals with type 1 diabetes the use of CSII pump resulted in better glucose control To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
  • SCOTT'S WEB LOG  |  FRIDAY, NOVEMBER 16, 2007
    [Clinical Trial, Type 1 Diabetes] The Business of Diabetes: Signs Suggest Lilly's Type 1 Diabetes Strategy May Be Evolving
    Since 1923, Eli Lilly and Company's strategy for type 1 diabetes has been fixated on insulin replacement, and more recently, pushing the idea of intensified insulin therapy. type 1 diabetes treatment market to rival Novo Nordisk and more recently, some share to Sanofi Aventis. This year, the company beefed up its salesforce for diabetes products to match Novo Nordisk's significant sales staff. Heine to manage Lilly's diabetes business.
  • TOPIX  |  WEDNESDAY, AUGUST 1, 2012
    [Clinical Trial, Type 1 Diabetes] The Sanford Project Reaches Milestone in Quest to Cure Type 1 Diabetes
    Sanford Project researchers have reached a critical milestone in a clinical trial testing a combination of two medications to determine if the drugs can help patients with type 1 diabetes keep their blood glucose levels under control with less or no insulin
  • JOSLIN DIABETES CENTER  |  WEDNESDAY, JULY 12, 2017
    [Clinical Trial, Type 1 Diabetes] Joslin Doctor Receives Clinical Research Award for Type 1 Diabetes Research
    is Director of the Beetham Eye Institute at Joslin Diabetes Center, and Professor of Ophthalmology and Vice Chair of the Department of Ophthalmology at Harvard Medical School. Robert Levine Excellence in Clinical Research Award. Dr. Aiello is Director of the Beetham Eye Institute at Joslin Diabetes Center, and Professor of Ophthalmology and Vice Chair of the Department of Ophthalmology at Harvard Medical School. Lloyd Paul Aiello, M.D., Ph.D.,
  • SCIENCE DAILY  |  SUNDAY, JUNE 7, 2015
    [Clinical Trial, Type 1 Diabetes] Phase II trial of BCG vaccine to reverse type 1 diabetes launched
    A phase II clinical trial testing the ability of the generic BCG vaccine to reverse advanced type 1 diabetes has received approval from the US Food and Drug Administration. The trial will soon begin enrolling participants
  • SCIENCE DAILY  |  THURSDAY, AUGUST 15, 2013
    [Clinical Trial, Type 1 Diabetes] Type 1 diabetes study identifies subset of patients with strong response to therapy
    Primary results from a new clinical trial show that a discrete subset of patients with type 1 diabetes treated with the monoclonal antibody teplizumab (MacroGenics, Inc.) demonstrated especially robust response with greater preservation of C-peptide, a biomarker of islet cell function, compared to controls, suggesting that these patients could be identified prior to treatment
  • SCIENCE DAILY  |  TUESDAY, JUNE 9, 2015
    [Clinical Trial, Type 1 Diabetes] Step towards Type 1 Diabetes vaccine by using nanotherapy
    For the first time, liposomes that imitate cells in the process of natural death have been used to treat diabetes. The next steps are to confirm the efficacy in vivo with cells from patients and to carry out clinical trials to prevent the disease and to cure it
  • SCIENCE DAILY  |  THURSDAY, AUGUST 28, 2014
    [Clinical Trial, Type 1 Diabetes] New model predicts patients with type 1 diabetes who will go on to develop major complications
    A new model has been developed for predicting which patients with type 1 diabetes will go on to develop major complications, through easily and routinely measured risk factors. The risk estimates can guide surveillance recommendations, inform patients and allow efficient design and analysis of clinical trials," the author say
  • INSULIN NATION  |  WEDNESDAY, JUNE 7, 2017
    [Clinical Trial, Type 1 Diabetes] Medtronic Launches 670G – First Hybrid, Closed-Loop System
    The FDA approved the system for people with Type 1 diabetes ages 14 and older in September 2016. As Medtronic stated in its press release, researchers found in a pivotal clinical trial that use of the 670G helped users have less variability in glycemic levels, more time in a good glycemic target range, reduced risk of hyperglycemia and hypoglycemia, and somewhat improved A1C levels. The company recently has endured several issues with its diabetes product line.
  • INSULIN NATION  |  TUESDAY, JULY 29, 2014
    [Clinical Trial, Type 1 Diabetes] Insulin Cocktails, Mouse Cures, Group Appointments
    A new study is examining whether a common gout medication can help prevent kidney disease in people with Type 1 diabetes. Diabetes is the leading cause of kidney failure in the U.S. UCSF scientists have figured out a way to block diabetes in mice by preventing stressed-out cells from being killed off by the body. A Canadian study found that group sessions had a better outcome than individual appointments when it came to diabetes self-care.
  • SCOTT'S WEB LOG  |  FRIDAY, NOVEMBER 16, 2007
    [Clinical Trial, Type 1 Diabetes] The Business of Diabetes: Signs Suggest Lilly's Type 1 Diabetes Strategy May Be Evolving
    Since 1923, Eli Lilly and Company's strategy for type 1 diabetes has been fixated on insulin replacement, and more recently, pushing the idea of intensified insulin therapy. type 1 diabetes treatment market to rival Novo Nordisk and more recently, some share to Sanofi Aventis. This year, the company beefed up its salesforce for diabetes products to match Novo Nordisk's significant sales staff. Heine to manage Lilly's diabetes business.
  • SCOTT'S WEB LOG  |  MONDAY, MARCH 12, 2007
    [Clinical Trial, Type 1 Diabetes] Successful Islet Cell Transplant Without Immunosuppressive Therapy In Mice With Type 1 Diabetes
    Successful Islet Cell Transplant Without Immunosuppressive Therapy In Mice With Type 1 Diabetes Medical News Today Mar 12, 2007 Scientists at Weill Cornell Medical College may have reached a breakthrough in the search for a lasting cure for type 1 diabetes. Insulin-producing islet cells are deficient in type 1 diabetes. "If Scientists have sought to reverse type 1 diabetes by transplanting new islet cells.
  • SCOTT'S WEB LOG  |  MONDAY, MARCH 12, 2007
    [Clinical Trial, Type 1 Diabetes] Successful Islet Cell Transplant Without Immunosuppressive Therapy In Mice With Type 1 Diabetes
    Successful Islet Cell Transplant Without Immunosuppressive Therapy In Mice With Type 1 Diabetes Medical News Today Mar 12, 2007 Scientists at Weill Cornell Medical College may have reached a breakthrough in the search for a lasting cure for type 1 diabetes. Insulin-producing islet cells are deficient in type 1 diabetes. "If Scientists have sought to reverse type 1 diabetes by transplanting new islet cells.
  • LIVING WITH DIABETES  |  FRIDAY, APRIL 16, 2010
    [Clinical Trial, Type 1 Diabetes] My Symlin Journey
    Living Life with Diabetes Friday, April 16, 2010 My Symlin Journey When I started on symlin nearly 2 months ago I was incredibly concerned about the nausea since that was the single reason I dropped out of the clinical trial the first time I was on symlin. Had somebody told me back when I was a part of the clinical trial that I would be doing so well on symlin and, gasp, happy to be on it I would have thought you told me the world was flat.
  • SCIENCE DAILY  |  MONDAY, JUNE 16, 2014
    [Clinical Trial, Type 1 Diabetes] Bionic pancreas controls blood sugar levels in adults, adolescents with type 1 diabetes
    The latest version of a bionic pancreas device has been successfully tested in two five-day clinical trials -- one in adults, the other in adolescents -- that imposed minimal restrictions on patient activities
  • CHECK DIABETES  |  SATURDAY, JULY 31, 2010
    [Clinical Trial, Type 1 Diabetes] Herbal home remedies for diabetes mellitus - Check Diabetes
    Home Diabetes News Privacy Policy Contact Us Sitemap Herbal home remedies for diabetes mellitus Diabetes mellitus is a deadly disease if left untreated. Herbal remedies for diabetes are being practiced since 1500 BC. A lot of clinical trials and research work shows that herbal remedies for diabetes have been effective if taken along with a proper diabetic diet. It is also effective for treatment of diabetic retinopathy.
  • SCOTT'S WEB LOG  |  FRIDAY, JUNE 1, 2007
    [Clinical Trial, Type 1 Diabetes] Why We Need Full Disclosure of Drug Trials
    The latest news that the type 2 diabetes drug Avandia increased the risk of cardiovascular disease (heart attack, stroke) came into the public domain when researchers at the esteemed Cleveland Clinic published its findings in The New England Journal of Medicine last week. In that settlement, GlaxoSmithKline agreed to publicly disclose the results of its clinical trials for all of its other drugs, including Avandia.
  • SCOTT'S WEB LOG  |  FRIDAY, JUNE 1, 2007
    [Clinical Trial, Type 1 Diabetes] Why We Need Full Disclosure of Drug Trials
    The latest news that the type 2 diabetes drug Avandia increased the risk of cardiovascular disease (heart attack, stroke) came into the public domain when researchers at the esteemed Cleveland Clinic published its findings in The New England Journal of Medicine last week. In that settlement, GlaxoSmithKline agreed to publicly disclose the results of its clinical trials for all of its other drugs, including Avandia.
  • SARA KNICKS  |  FRIDAY, MAY 26, 2017
    [Clinical Trial, Type 1 Diabetes] Eye Drops for Diabetic Retinopathy May Replace Painful Eye Injections
    Eye drops may soon be used to treat diabetic retinopathy and prevent blindness, replacing painful and costly eye injections. Researchers from the University of Nottingham in the UK are looking into eye drops that can be used for patients with diabetic retinopathy and hope to offer these drops for clinical trial patients within the next three to […]. News Treatments Type 1 Diabetes Type 2 Diabetes diabetes news diabetic retinopathy retinopathy
  • JOSLIN DIABETES CENTER  |  MONDAY, NOVEMBER 9, 2015
    [Clinical Trial, Type 1 Diabetes] Resetting the Immune System
    Throughout National Diabetes Month, we will be sharing developments into Joslin’s unique approach for a permanent cure for type 1 diabetes. Our mission is to prevent, treat and cure diabetes so that one day there will be a world free of diabetes and its complications. Curing type 1 diabetes requires a combination of three strategies. Type 1 diabetes is a disease of a broken immune system.
  • DIABETES HEALTH  |  MONDAY, JANUARY 24, 2011
    [Clinical Trial, Type 1 Diabetes] Mannkind's Inhalable Insulin, Afrezza, Put Back on Hold by the FDA
    What the FDA wants now is a couple more clinical trials with the new form of the inhaler (one in patients with type 1 diabetes and one in patients with type 2 diabetes), with at least one trial including a treatment group using the older form of the inhaler, in order to obtain a head-to-head comparison of the two devices
  • INSULIN NATION  |  WEDNESDAY, OCTOBER 22, 2014
    [Clinical Trial, Type 1 Diabetes] Beta Cell Shield, Mom’s Genetic T1D Role, Probiotics
    Insulin Nation takes a look at some of the most notable Type 1 diabetes research results: The Beta Cell Shield. One of the biggest hurdles to finding a functional cure for Type 1 diabetes is that the body doesn’t want to stop killing off insulin-producing beta cells. Now, an Israeli company is conducting an 8-person clinical trial of an implantable device designed to house implanted beta cells and keep them alive while they produce insulin.
  • INSULIN NATION  |  MONDAY, FEBRUARY 6, 2017
    [Clinical Trial, Type 1 Diabetes] How the Trump Immigration Ban Might Affect Diabetes Research
    Earlier, we reported on how the Trump administration’s executive order on immigration barred Dr. Samira Asgari from joining a research lab that does diabetes research. The attorneys general argued, among other points, that their states are home to research and clinical facilities that rely upon foreign-born graduate students and professionals, and that the exclusion of that workforce will impact the citizens of those two states. Want more Type 1 news?
  • INSULIN NATION  |  MONDAY, JUNE 30, 2014
    [Clinical Trial, Type 1 Diabetes] Afrezza Has Lift-Off with FDA Approval
    On June 27th, 2014, the FDA sent notice that it has approved Afrezza as a bolus insulin for adults with Type 1 and Type 2 diabetes, with some restrictions. FDA regulators agreed with the recommendation of its scientific advisory board that clinical trial results proved the inhalable insulin is safe for use and does what it is supposed to do as a rapid-acting insulin.
  • TOPIX  |  FRIDAY, FEBRUARY 5, 2016
    [Clinical Trial, Type 1 Diabetes] Diabetes Cure? Type 1 Stem Cell Capsule Treatment in Trials
    A Type 1 diabetes cure through promising stem cell treatment is currently in the clinical trial stage and could eliminate blood glucose monitor and insulin injections, according to Fortune magazine. the company conducting the clinical trial, announced Thursday it was joining forces with Janssen Biotech Inc. to help boost its work in stem cell treatment for Type 1 diabetes
  • SCOTT'S WEB LOG  |  SUNDAY, MARCH 25, 2007
    [Clinical Trial, Type 1 Diabetes] The Business of Diabetes: Beckman Coulter News
    On the surface, it would not appear directly relevant to diabetes as few people with diabetes have ever heard of the company involved. However, few people realize that in 2004, the Massachusetts General Hospital trustees established a relationship with Beckman Coulter in order to significantly discount $1,000,000 of equipment needed to establish the blood assay for Denise Faustman's and David Nathan's human clinical trials.
  • SCOTT'S WEB LOG  |  SUNDAY, MARCH 25, 2007
    [Clinical Trial, Type 1 Diabetes] The Business of Diabetes: Beckman Coulter News
    On the surface, it would not appear directly relevant to diabetes as few people with diabetes have ever heard of the company involved. However, few people realize that in 2004, the Massachusetts General Hospital trustees established a relationship with Beckman Coulter in order to significantly discount $1,000,000 of equipment needed to establish the blood assay for Denise Faustman's and David Nathan's human clinical trials.
  • INSULIN NATION  |  MONDAY, NOVEMBER 18, 2013
    [Clinical Trial, Type 1 Diabetes] The Mouse Trap
    Are you sick of reading headlines proclaiming a cure for diabetes is at hand….for The NOD (non-obese diabetic) mouse, a line bred to develop T1, is the subject of choice for almost all early-stage diabetes research. If a procedure works in mice, it’s big news, and human trials are often the next logical step. So why have we cured diabetes in mice more than 400 times, but the same procedures have never cured a human being?
  • SCOTT'S WEB LOG  |  WEDNESDAY, JUNE 6, 2012
    [Clinical Trial, Type 1 Diabetes] New C-Peptide Assay Could Expand The Universe of Eligible Participants in Immune System Interventions
    This month, diabetes researcher/immunologist and associate professor at Harvard Medical School, Dr. Denise Faustman's work is profiled in a trade magazine you've likely never encountered before: the American Association for Clinical Chemistry's Clinical Laboratory News , that article may be found at [link]. (It That's a trade publication geared mainly towards people who work for clinical laboratories (you know, like Quest Diagnostics, LabCorp, hospital labs and others).
  • INSULIN NATION  |  TUESDAY, JULY 15, 2014
    [Clinical Trial, Type 1 Diabetes] A D-Dad’s Dispatch from Friends for Life
    We planned, we saved, we applied for scholarships, and all that work payed off when we arrived at the Children With Diabetes 2014 Friends For Life Conference in Orlando, Florida. We drove some 1200 miles with a baby, a pre-teen, and 2 girls with Type 1 diabetes to get to this four-day event, and it was all worth it. People with Type 1 Diabetes get green ones, people with Celiac get yellow, and non-diabetics like me get orange.
  • TOPIX  |  SATURDAY, NOVEMBER 26, 2011
    [Clinical Trial, Type 1 Diabetes] Diabetes medicine, syringe, blood glucose monitor
    Kerry Morgan was just 3 years old when she participated in her first clinical trial for type 1 diabetes prevention
  • TOPIX  |  WEDNESDAY, FEBRUARY 6, 2013
    [Clinical Trial, Type 1 Diabetes] Diabetes vaccine volunteers sought
    Researchers at Cardiff University are taking part in a clinical trial of a new vaccine to tackle type 1 diabetes
  • INSULIN NATION  |  MONDAY, JUNE 29, 2015
    [Clinical Trial, Type 1 Diabetes] 12 Ways to Stay Safe with an Insulin Pump
    Integrated Diabetes Services (IDS) provides detailed advice and coaching on diabetes management from certified diabetes educators and dieticians. Insulin Nation hosts a regular Q&A column from IDS that answers questions submitted from the Type 1 diabetes community. Technology has made astounding leaps and bounds in diabetes management, especially in the past decade.
  • INSULIN NATION  |  SUNDAY, FEBRUARY 8, 2015
    [Clinical Trial, Type 1 Diabetes] Tandem’s High-Capacity Pump
    While 200-unit and 300-unit pumps have been on the market since 2007, a 480-unit pump can provide more options for daily diabetes care, he says. The t:flex pump reservoir is designed for three days’ usage for people who require more than 100 units of U-100 insulin per day, such as teenagers with Type 1 diabetes, and many people with Type 2. More than 400,000 Americans with Type 1 diabetes and approximately 75,000 with Type 2 are pump users.
  • SCOTT'S WEB LOG  |  FRIDAY, FEBRUARY 8, 2008
    [Clinical Trial, Type 1 Diabetes] Competition in Patents for "SmartInsulin"?
    As my readers know, I think one of the most promising developments in terms of treating patients with type 1 diabetes is the concept of " SmartInsulin ". It is known that Novo has no "Smart Insulin" undergoing clinical trials (any phase) at this time, as that information is disclosed on the company's website under the heading " R&D Pipeline ". insulin type 1 diabetes "Smart Insulin" SmartCells 2008
  • SCOTT'S WEB LOG  |  WEDNESDAY, MARCH 5, 2008
    [Clinical Trial, Type 1 Diabetes] The FDA Needs Your Input on Diabetes Medicines!
    On Tuesday, I wrote about the opportunity for people with diabetes to attend the NIH/NIDDK's jointly-sponsored (along with JDRF) "Artificial Pancreas Workshop" in July. Insulin is perhaps the most visible example of a biologic used to treat diabetes, but some newer treatments such as Byetta used in the treatment of type 2 diabetes also falls within this category.
  • SCOTT'S WEB LOG  |  WEDNESDAY, MARCH 5, 2008
    [Clinical Trial, Type 1 Diabetes] The FDA Needs Your Input on Diabetes Medicines!
    On Tuesday, I wrote about the opportunity for people with diabetes to attend the NIH/NIDDK's jointly-sponsored (along with JDRF) "Artificial Pancreas Workshop" in July. Insulin is perhaps the most visible example of a biologic used to treat diabetes, but some newer treatments such as Byetta used in the treatment of type 2 diabetes also falls within this category.
  • SCOTT'S WEB LOG  |  THURSDAY, AUGUST 2, 2007
    [Clinical Trial, Type 1 Diabetes] Show Me The Money!
    August 1 marked the start of JDRF's " Promise to Remember Me " campaign. A major objective of the campaign this year is to convince the Federal Government to renew the Special Statutory Funding Program for Type 1 Diabetes Research , which is set to expire in 2008. What's at stake is more than one-third (35% to be exact) of all Federal funding allocated to type 1 diabetes research which comes from that "special" program.
  • SCOTT'S WEB LOG  |  THURSDAY, AUGUST 2, 2007
    [Clinical Trial, Type 1 Diabetes] Show Me The Money!
    August 1 marked the start of JDRF's " Promise to Remember Me " campaign. A major objective of the campaign this year is to convince the Federal Government to renew the Special Statutory Funding Program for Type 1 Diabetes Research , which is set to expire in 2008. What's at stake is more than one-third (35% to be exact) of all Federal funding allocated to type 1 diabetes research which comes from that "special" program.
  • TOPIX  |  SATURDAY, MARCH 8, 2014
    [Clinical Trial, Type 1 Diabetes] New Market Study Published: Juvenile Diabetes Research Foundation -.
    The company provides research and development service for type 1 diabetes. It provides grants for diabetes clinical trials to laboratories, educational institutions, and pharmaceutical and medical research companies
  • TOPIX  |  MONDAY, SEPTEMBER 14, 2015
    [Clinical Trial, Type 1 Diabetes] Researchers studying whether gout drug prevents progression of kidney damage in diabetes patients
    14, 2015 UT Southwestern Medical Center has joined an international clinical trial studying whether a drug traditionally used to treat gout can help prevent kidney damage in patients with Type 1 diabetes DALLAS Sept.
  • SCOTT'S WEB LOG  |  FRIDAY, FEBRUARY 8, 2008
    [Clinical Trial, Type 1 Diabetes] Competition in Patents for "SmartInsulin"?
    As my readers know, I think one of the most promising developments in terms of treating patients with type 1 diabetes is the concept of " SmartInsulin ". It is known that Novo has no "Smart Insulin" undergoing clinical trials (any phase) at this time, as that information is disclosed on the company's website under the heading " R&D Pipeline ". insulin type 1 diabetes "Smart Insulin" SmartCells 2008
  • TOPIX  |  THURSDAY, NOVEMBER 3, 2011
    [Clinical Trial, Type 1 Diabetes] New study helps kids monitor diabetes
    This sensor will be placed under a child's skin as part of a clinical trial to help children better manage Type 1 diabetes
  • SCOTT'S WEB LOG  |  THURSDAY, JANUARY 11, 2007
    [Clinical Trial, Type 1 Diabetes] You Read It Here First!
    And in the face of an epidemic of diabetes, the governors are asking why there is no cheaper generic version of a drug that, in one form or another, has been used since the 1920s. People with diabetes in this country, as well as government and private insurers, spend a combined $3.3 Now, as the nation's diabetes rate climbs, political pressure is mounting on the Food and Drug Administration to open the door to generic versions.
  • SCOTT'S WEB LOG  |  THURSDAY, JANUARY 11, 2007
    [Clinical Trial, Type 1 Diabetes] You Read It Here First!
    And in the face of an epidemic of diabetes, the governors are asking why there is no cheaper generic version of a drug that, in one form or another, has been used since the 1920s. People with diabetes in this country, as well as government and private insurers, spend a combined $3.3 Now, as the nation's diabetes rate climbs, political pressure is mounting on the Food and Drug Administration to open the door to generic versions.
  • DIABETES TECHNOLOGY BLOG  |  SATURDAY, FEBRUARY 9, 2008
    [Clinical Trial, Type 1 Diabetes] Diabetes Technology Blog: Meeting Dr. Faustman
    Diabetes Technology Blog Sunday, February 10, 2008 Meeting Dr. Faustman In early January I visited the Mass General Hospital research lab where Dr. Denise Faustman is leading research into a possible cure for type 1 diabetes. The lab is drawing samples of blood from people with type 1 diabetes, and healthy volunteers. Because theyre having trouble getting healthy volunteers, they ask everyone with diabetes to bring a volunteer with them.
  • DIABETES MINE  |  WEDNESDAY, NOVEMBER 10, 2010
    [Clinical Trial, Type 1 Diabetes] Crowdsourcing Our Diabetes Smarts – Thoughts from Red Maxwell
    Home Diabetes Essentials Personal Stories Products Food D-News Examined Health 2.0 Books & Resources Fun Stuff Marketplace Recent Posts Small But Mighty: Paying It Forward with Graphic Design Announcing: DiabetesMine Teams with Alliance Health Snappy Comebacks for Parents of Diabetic Kids (Or…) On Complications: The 411 on Diabetic Eyes Much Ado About Environmental Chemicals & Diabetes In Case of Emergency: Good D-Scouts Are Prepared Just How Hot Are We for Inhalable Insulin?
  • SCOTT'S WEB LOG  |  THURSDAY, JUNE 9, 2011
    [Clinical Trial, Type 1 Diabetes] Teplizumab and DPT-1: "Not Dead Yet"?
    How many of my readers remember an experimental anti-CD3 monoclonal antibody treatment called teplizumab that had trials with a cutesy name: Protégé? That trial was being undertaken by a closely-hold, Maryland-developer named Macrogenics, Inc. You might, because these products have been promoted as a promising autoimmunity treatment for type 1 diabetes for a while now. the third was the Diamyd trial which was NOT facilitated by the JDRF).
  • JOSLIN DIABETES CENTER  |  FRIDAY, AUGUST 2, 2013
    [Clinical Trial, Type 1 Diabetes] Wearing the Bionic Pancreas: An Interview with a User
    Edward Damiano, the creator of the bionic pancreas currently undergoing trials, speaking at the Joslin Symposium on type 1 diabetes earlier this year. Scott Scolnick is a sales territory manger for Tandem Diabetes Care, Inc. He is also a person who has had type 1 diabetes for about 35 years. He received the news that he had type 1 as a 15 year old vacationing in Israel. How did you react when the trial was over?
  • TOPIX  |  SUNDAY, JUNE 7, 2015
    [Clinical Trial, Type 1 Diabetes] Type I diabetes cure? MGH researchers say new drug could be the answer
    Scientists at Massachusetts General Hospital are hoping to prove that type 1 diabetes can be reversed with the help of a generic drug. The five-year long, phase II clinical trial , which received approval from the U.S. Food and Drug Administration, was announced Sunday during the 75th Scientific Sessions of the American Diabetes Association , one of the largest diabetes gathering in the country
  • YOUR DIABETES MAY VARY  |  MONDAY, JANUARY 9, 2012
    [Clinical Trial, Type 1 Diabetes] JDRF IDDP with KalVista Pharmaceuticals
    From the News Wire: KalVista Pharmaceuticals and JDRF form research partnership focused on novel approach for treating diabetic eye disease Southampton, UK and New York, USA 09 January 2012 - KalVista Pharmaceuticals ("KalVista") and JDRF have formed a research partnership focused on a novel approach being developed by KalVista to preserve vision and slow the progression of diabetic eye disease.
  • TOPIX  |  MONDAY, JANUARY 4, 2016
    [Clinical Trial, Type 1 Diabetes] Artificial pancreas to undergo long-term clinical tests
    Researchers will soon undertake one of the largest-ever long-term clinical trials of a system designed to help regulate blood sugar levels of individuals with type 1 diabetes mellitus. If the so-called artificial pancreas system performs in patients as hoped, it could lead to commercial trials and eventual regulatory approval in the United States and abroad
  • DIABETES TECHNOLOGY BLOG  |  THURSDAY, MARCH 13, 2008
    [Clinical Trial, Type 1 Diabetes] Diabetes Technology Blog: Type 1 cure trials start
    Diabetes Technology Blog Thursday, March 13, 2008 Type 1 cure trials start This is the most exciting news Ive had since my diagnosis with diabetes 25 years ago. Today ClinicalTrial.gov posted a trial announcement looking for people to participate in the first trial for a possible cure for type 1 diabetes. To quote the site "This is the first step in trying to cure established type 1 diabetes".
  • JOSLIN DIABETES CENTER  |  THURSDAY, FEBRUARY 16, 2017
    [Clinical Trial, Type 1 Diabetes] The Future of Complications Treatments Could Get Personal
    Joslin Diabetes Center has been at the forefront of tailored medical care for more than 100 years. Joslin himself realized the importance of individualizing diabetes treatment for each patient, and that philosophy continues today with the clinic’s Joslin Care model. But new developments in the laboratories of Joslin’s research department could soon bring personalized diabetes medicine to a whole new level. Chief Scientific Officer at Joslin Diabetes Center.
  • SCOTT'S WEB LOG  |  FRIDAY, FEBRUARY 16, 2007
    [Clinical Trial, Type 1 Diabetes] This Week's News Update
    There were a number of important news developments during the past week that impact people with diabetes, therefore I have summarized all of them here. For example, the trial court has already ruled in CIRM's favor, and on February 14, 2007, an appellate court heard oral arguments on the appeal filed by Prop 71's opponents. Biologic drugs may be used to treat diseases such as cancer, diabetes and AIDS. Pfizer apparently sees the world diabetes market as too sweet to ignore.
  • SCOTT'S WEB LOG  |  FRIDAY, FEBRUARY 16, 2007
    [Clinical Trial, Type 1 Diabetes] This Week's News Update
    There were a number of important news developments during the past week that impact people with diabetes, therefore I have summarized all of them here. For example, the trial court has already ruled in CIRM's favor, and on February 14, 2007, an appellate court heard oral arguments on the appeal filed by Prop 71's opponents. Biologic drugs may be used to treat diseases such as cancer, diabetes and AIDS. Pfizer apparently sees the world diabetes market as too sweet to ignore.
  • SCOTT'S WEB LOG  |  TUESDAY, DECEMBER 11, 2007
    [Clinical Trial, Type 1 Diabetes] More Discrediting of "Disease Management" Programs
    Diabetes is perhaps the condition most often targeted by such disease management programs because it is relatively easy to do a glycosated hemoglobin (better known as the hemoglobin A1C) blood test to show reported progress (or lack thereof), while other chronic conditions are more difficult to quantify results. Just because one type of intervention can benefit one disease, that doesn't mean it will work the same way for another disease," Mattke said.
  • SCOTT'S WEB LOG  |  TUESDAY, DECEMBER 11, 2007
    [Clinical Trial, Type 1 Diabetes] More Discrediting of "Disease Management" Programs
    Diabetes is perhaps the condition most often targeted by such disease management programs because it is relatively easy to do a glycosated hemoglobin (better known as the hemoglobin A1C) blood test to show reported progress (or lack thereof), while other chronic conditions are more difficult to quantify results. Just because one type of intervention can benefit one disease, that doesn't mean it will work the same way for another disease," Mattke said.
  • INSULIN NATION  |  MONDAY, JUNE 23, 2014
    [Clinical Trial, Type 1 Diabetes] Better Insulin, Redefining Diabetes, & Good Glucagon
    You may have read a headline or two about the success of Boston University’s artificial pancreas trials, announced at the 2014 ADA Scientific Sessions. Each year, more than 15,000 experts in the field of diabetes convene at the American Diabetes Association’s Scientific Sessions to hear the latest news in diabetes research, medical devices, and clinical practices. With those recommendations came new A1C guidelines for children with diabetes.
  • INSULIN NATION  |  MONDAY, FEBRUARY 1, 2016
    [Clinical Trial, Type 1 Diabetes] Filming the ViaCyte Type 1 Stem Cell Experiment
    Research into possible functional cures for Type 1 diabetes is often open-ended, with no guarantee of success. Lisa Hepner is a director of documentary films, and she has Type 1 diabetes. As she was recovering at the hospital in 2008 from a dangerous nighttime low, her business partner (and now husband) Guy Mossman said to her, “We should make a film about diabetes.” FDA granted expedited review of the proposal, and cleared the human trial in 2014.
  • SCOTT'S WEB LOG  |  TUESDAY, NOVEMBER 15, 2011
    [Clinical Trial, Type 1 Diabetes] The Business of Diabetes: Geron No Mo!
    The company conducting the first ever FDA-sanctioned clinical trial in the U.S. of a therapy using human embryonic stem cells said that it was stopping that trial and exiting the stem cell business (see [link] for The New York Times article on this) altogether. Of particular interest to the type 1 diabetes community is what Geron referred to as pancreatic islet cells (known as "GRNIC1") for diabetes.
  • SCOTT'S WEB LOG  |  TUESDAY, OCTOBER 11, 2011
    [Clinical Trial, Type 1 Diabetes] A Parallel Autoimmune Online Community
    So I did not officially "participate" this year as some of my fellow diabetes blogging counterparts did, but shortly before Invisible Illness Week, I did something else. I began following a few individuals with various OTHER autoimmune diseases besides type 1 diabetes. Plus, most (except, perhaps psoriasis) autoimmune diseases are actually invisible illnesses, not unlike type 1 diabetes.
  • YOUR DIABETES MAY VARY  |  WEDNESDAY, MARCH 28, 2012
    [Clinical Trial, Type 1 Diabetes] iCo Therapeutics and JDRF Team Up
    The iDEAL study is a Phase II clinical trial to evaluate whether the drug iCo-007 could help to treat DME in people with either T1D or type 2 diabetes.
  • TOPIX  |  WEDNESDAY, SEPTEMBER 16, 2015
    [Clinical Trial, Type 1 Diabetes] Diabetes Research Institute's first patient in BioHub trial no longer requires insulin therapy
    The Diabetes Research Institute , a Center of Excellence at the University of Miami Miller School of Medicine, has announced that the first patient in its clinical trial has been free from insulin injections in record time following the implantation of islet cells within a biological scaffold. In this pilot study, DRI researchers are testing a new transplant technique for insulin-producing cells, building upon decades of progress in clinical islet transplantation
  • DIABETES STORIES  |  SUNDAY, SEPTEMBER 14, 2014
    [Clinical Trial, Type 1 Diabetes] JDRF hosts free NYC ONE Expo Sept 16th
    From 3-8 PM ONE Expo will bring families and individuals - children and adults- affected by type 1 diabetes together to learn, engage and be empowered. 18th Street, NYC Schedule 3-8 PM there will be vendors in diabetes technology and treatment demonstrating their wares. 4-4:45 PM - Tips and Tricks for daily T1D management, a discussion led by a panel of people living with type 1. JDRF is hosting an informational event this Wednesday in Manhattan.
  • JOSLIN DIABETES CENTER  |  MONDAY, MARCH 19, 2012
    [Clinical Trial, Type 1 Diabetes] Who Said Bigger is Better?
    Researchers have started to experiment with nanotherapeutics as a way to prevent and treat type 1 diabetes. Clinical trials for this technology may be years away, but small and targeted might be the way to go on the road to better clinical care. Only between 1 and 100 nanometers (nm) in size (a pin head is 1,500,000 nm), these cells are highly specific cargo carriers with sophisticated homing devices on board. By Nora Saul, M.S., C.D.E.,
  • INSULIN NATION  |  MONDAY, JUNE 20, 2016
    [Clinical Trial, Type 1 Diabetes] The FDA Describes Efforts to Speed Up Artificial Pancreas Development
    The Diabetes Patient Advocacy Coalition (DPAC) and the FDA paired up to host a webinar on the FDA’s efforts to speed up its premarket regulatory approval process for the artificial pancreas. During the webinar, the FDA also signaled its goal to make the technology suitable for insulin therapy for children with diabetes. This is in addition to the clinical trial design and glucose control outcomes which are the traditional focus of the FDA’s review.
  • INSULIN NATION  |  THURSDAY, OCTOBER 12, 2017
    [Clinical Trial, Type 1 Diabetes] Pump Therapy to the Rescue for Type 2 Diabetes?
    When I first learned that I had Type 2 diabetes in 2001, I thought my world had come crumbling down right before my eyes. Having grown up in a household where diabetes runs in the family, all I could picture for the future was having to test my urine, take frequent naps, and dodge the complications that can arise from the disease. That most likely was part of the problem, but diabetes is different for everyone, and it was proving especially difficult for me.
  • INSULIN NATION  |  TUESDAY, OCTOBER 6, 2015
    [Clinical Trial, Type 1 Diabetes] Old Drug, New Tricks for Type 1?
    Researchers have long known that diabetes runs in families, but it’s only been about 20 years since they have successfully isolated gene and antibody combinations that serve as reliable genetic predictors of the risk of developing Type 1 diabetes. A great many people who have Type 1 also have inherited genetic codes for antigens known as DR4 and DQ8; an antigen is any substance that may cause your body to produce antibodies against it.
  • YOUR DIABETES MAY VARY  |  MONDAY, SEPTEMBER 8, 2008
    [Clinical Trial, Type 1 Diabetes] From The News Wire: Biodel Preliminary Results
    Wall Street isn't happy: [link] Biodel Announces Preliminary Results of Pivotal Phase III Clinical Trials for VIAject(TM) DANBURY, Conn.--(BUSINESS BUSINESS WIRE)--At the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Rome, Biodel Inc. Based on the initial analyses, both clinical trials met the primary endpoint of non-inferior mean change in HbA1c over six months of treatment.
  • INSULIN NATION  |  FRIDAY, MAY 19, 2017
    [Clinical Trial, Type 1 Diabetes] Fiasp Again Goes Before the FDA for Approval
    A new mealtime insulin that has been shown to improve glycemic control for people with Type 1 Diabetes is once again before the FDA for approval. Novo states that Fiasp appears twice as fast in the bloodstream as Novo’s NovoRapid in clinical trials. Novo reports that more 2,100 people with Type 1 Diabetes and Type 2 Diabetes participated in the four-stage trial program in Canada. Want more Type 1 news?
  • INSULIN NATION  |  FRIDAY, JUNE 3, 2016
    [Clinical Trial, Type 1 Diabetes] Researchers Testing SGLT2 Drugs for Type 1 Use
    Pharma companies are testing whether drugs designed for combatting Type 2 diabetes can be used to also treat Type 1 diabetes. There have been roughly 100 clinical trials involving SGLT2 drugs logged at the National Institutes of Health since researchers first began evaluating canagliflozin. All but two have involved individuals with Type 2 diabetes or those who don’t have diabetes. Want more Type 1 news?
  • MY NEW ISLETS  |  MONDAY, MAY 9, 2011
    [Clinical Trial, Type 1 Diabetes] Group Blog Week - Admiring our Differences
    Johnson at Scott's Diabetes. He so obviously enjoys interacting with other diabetics, despite the fact that the thing we have in common is an unfortunate part to our lives. The second blog is written by Joshua Levy at Current Research into a Cure for Type 1 Diabetes. He writes about the most current clinical trials and how they are progressing. His motivation is his daughter who is a Type 1 diabetic.
  • INSULIN NATION  |  TUESDAY, OCTOBER 4, 2016
    [Clinical Trial, Type 1 Diabetes] Why You Still Have to Bolus with the First Artificial Pancreas
    JDRF, along with the Helmsley Charitable Trust and the National Institutes of Health’s Special Diabetes Program, spearheaded the philanthropic giving to fund research into artificial pancreas development. There has been vocal criticism among some in the Type 1 diabetes community that the 670G is not automated enough to be considered an artificial pancreas. Medtronic is currently conducting clinical trials of the 670G for pediatric use.
  • MY NEW ISLETS  |  MONDAY, MAY 14, 2012
    [Clinical Trial, Type 1 Diabetes] If you don't already follow Joshua Levy's blog, you should!
    In his blog, he is constantly scrutinizing the research for the cure of Type 1 diabetes. He is the parent of a Type 1, so his motivation to do this is obvious. He has a clear definition on what he considers to be the cure and keeps track of the clinical trials as they progress towards this goal. He also gives credit to where the funding comes for these trials. I made a poster for my JDRF walk which shows which trials are funded by the JDRF.
  • YOUR DIABETES MAY VARY  |  WEDNESDAY, APRIL 9, 2008
    [Clinical Trial, Type 1 Diabetes] From the News Wire: Tolerx Phase III
    Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting Phase III study will evaluate effects of otelixizumab, an investigational anti-CD3 monoclonal antibody, on preservation of endogenous insulin secretion CAMBRIDGE, Mass., WOW lots of news out today! Here another one, one of the JDRF IDDP companies.
  • YOUR DIABETES MAY VARY  |  WEDNESDAY, OCTOBER 22, 2008
    [Clinical Trial, Type 1 Diabetes] From The News Wire: $1Million JDRF IDDP with SmartCells
    and Juvenile Diabetes Research Foundation Announce Partnership and $1 Million Funding to Advance SmartInsulin(TM) for Type 1 Diabetes Wednesday October 22, 8:32 am ET Novel Insulin Formulation Provides for Glucose-regulated Insulin Delivery BEVERLY, Mass. and the Juvenile Diabetes Research Foundation (JDRF) today announced a partnership to advance SmartCells’ SmartInsulin™ for the treatment of type 1 diabetes. SmartCells, Inc.
  • INSULIN NATION  |  WEDNESDAY, OCTOBER 28, 2015
    [Clinical Trial, Type 1 Diabetes] Could Formoterol be the New Glucagon?
    Nearly 100 years ago, researchers discovered a new drug that changed diabetes care forever. Scientists are now testing existing drugs to see if they might provide effective treatments for Type 1 diabetes. Recently, it was reported that scientists were testing the hypertension drug methyldopa to see if it could delay the onset of Type 1. The study involved 14 participants, half of whom had Type 1 diabetes and half of whom did not.
  • INSULIN NATION  |  WEDNESDAY, OCTOBER 28, 2015
    [Clinical Trial, Type 1 Diabetes] Could Formoterol be the New Glucagon?
    Nearly 100 years ago, researchers discovered a new drug that changed diabetes care forever. Scientists are now testing existing drugs to see if they might provide effective treatments for Type 1 diabetes. Recently, it was reported that scientists were testing the hypertension drug methyldopa to see if it could delay the onset of Type 1. The study involved 14 participants, half of whom had Type 1 diabetes and half of whom did not.
<< 1 2 3 4 >>